دورية أكاديمية
أعرض في EDS

Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients.

التفاصيل البيبلوغرافية
العنوان: Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients.
المؤلفون: Qi JP; Department of Pathology, First Clinical Hospital, Harbin Medical University, Harbin 150001, PR China., Yang YL, Zhu H, Wang J, Jia Y, Liu N, Song YJ, Zan LK, Zhang X, Zhou M, Gu YH, Liu T, Hicks DG, Tang P
المصدر: Breast cancer : basic and clinical research [Breast Cancer (Auckl)] 2012; Vol. 6, pp. 1-8. Date of Electronic Publication: 2011 Dec 06.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: SAGE Publications Country of Publication: United States NLM ID: 101474356 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1178-2234 (Electronic) Linking ISSN: 11782234 NLM ISO Abbreviation: Breast Cancer (Auckl) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: <2016- > : Thousand Oaks, CA : SAGE Publications
Original Publication: [Auckland, N. Z.] : Libertas Academica
مستخلص: Background: Recent studies have shown that androgen displays an inhibitory effect on breast cancer cell lines that express androgen receptor (AR) but not estrogen receptor (ER) and progesterone receptor (PR). We have previously reported that approximately 1/3 of ER negative high grade invasive ductal carcinomas express AR. Thus, AR can serve as a potential therapeutic target for this group of patients.
Aim: Here we investigated AR expression patterns in 980 consecutive breast carcinomas.
Results: We found that (1) AR was expressed more frequently (77%) than ER (61%) and PR (60%) in breast carcinomas; (2) AR expression was associated with ER and PR expression (P < 0.0001), small tumor size (P = 0.0324) and lower Ki-67 expression (P = 0.0013); (3) AR expression was found in 65% of ER negative tumors; (4) AR expression was associated with PR and Ki-67 in ER negative tumors, but not in ER positive tumors; (5) AR expression was higher in ER positive subtypes (Luminal A, Luminal B and Luminal HER2 subtypes, 80%-86%) and lower in ER negative subtypes [HER2, triple negative (TN), and TN EFGR positive subtypes; 52%-66%], with over 50% of TN tumors expressing AR.
Conclusion: More breast carcinomas express AR than ER and PR, including significant numbers of ER negative and TN tumors, for which AR could serve as a potential therapeutic target.
References: Virchows Arch. 2006 Jul;449(1):24-30. (PMID: 16628414)
BMC Cancer. 2008 May 28;8:149. (PMID: 18507821)
Nature. 2000 Aug 17;406(6797):747-52. (PMID: 10963602)
Curr Oncol. 2011 Aug;18(4):161-4. (PMID: 21874112)
Am J Clin Pathol. 2008 Mar;129(3):398-409. (PMID: 18285262)
Arch Surg. 2003 Aug;138(8):879-83. (PMID: 12912747)
Med Mol Morphol. 2010 Jun;43(2):75-81. (PMID: 20683693)
Ann Oncol. 2010 Mar;21(3):488-492. (PMID: 19887463)
J Clin Oncol. 2010 Jun 1;28(16):2784-95. (PMID: 20404251)
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23. (PMID: 12829800)
Mod Pathol. 2006 Feb;19(2):264-71. (PMID: 16341146)
Hum Pathol. 2008 Mar;39(3):386-92. (PMID: 18187183)
Cancer. 2003 Aug 15;98(4):703-11. (PMID: 12910513)
Mod Pathol. 2010 Feb;23(2):205-12. (PMID: 19898421)
Nat Rev Clin Oncol. 2010 Dec;7(12):683-92. (PMID: 20877296)
J Clin Oncol. 2001 Feb 15;19(4):980-91. (PMID: 11181660)
Clin Cancer Res. 2004 Aug 15;10(16):5367-74. (PMID: 15328174)
J Natl Cancer Inst. 2009 May 20;101(10):736-50. (PMID: 19436038)
Curr Med Chem. 2011;18(4):513-22. (PMID: 21143113)
Histopathology. 2010 Dec;57(6):877-84. (PMID: 21166701)
Int J Clin Oncol. 2008 Oct;13(5):431-5. (PMID: 18946753)
Cancer Res. 2006 Aug 1;66(15):7775-82. (PMID: 16885381)
Breast Cancer Res Treat. 2001 Jun;67(3):245-53. (PMID: 11561770)
Virchows Arch. 2010 Oct;457(4):467-76. (PMID: 20809337)
Breast Cancer Res. 2008;10(5):404; author reply 405. (PMID: 18831725)
World J Surg. 2007 May;31(5):1041-6. (PMID: 17429562)
Arch Surg. 2004 Jan;139(1):50-4. (PMID: 14718276)
Cancer J. 2010 Jan-Feb;16(1):62-5. (PMID: 20164692)
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74. (PMID: 11553815)
Cancer. 2010 Mar 15;116(6):1431-9. (PMID: 20131351)
Mod Pathol. 2011 Jul;24(7):924-31. (PMID: 21552212)
Future Oncol. 2008 Feb;4(1):15-21. (PMID: 18240997)
Folia Histochem Cytobiol. 2008;46(3):269-76. (PMID: 19056529)
Am J Clin Pathol. 2003 Nov;120(5):725-31. (PMID: 14608899)
Clin Cancer Res. 2011 Apr 1;17(7):1867-74. (PMID: 21325075)
Endocr J. 2008 Jul;55(3):455-63. (PMID: 18480557)
Cancer. 2007 Jan 1;109(1):25-32. (PMID: 17146782)
Ann Oncol. 2009 Aug;20(8):1319-29. (PMID: 19535820)
J Clin Oncol. 1999 Sep;17(9):2639-48. (PMID: 10561337)
J Surg Oncol. 2007 May 1;95(6):437-9. (PMID: 17192921)
Breast Cancer (Auckl). 2010 May 20;4:35-41. (PMID: 20697531)
فهرسة مساهمة: Keywords: HER2; Ki-67; androgen receptor; breast cancer; estrogen receptor; molecular classification; progesterone receptor
تواريخ الأحداث: Date Created: 20120120 Date Completed: 20120823 Latest Revision: 20211021
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC3256731
DOI: 10.4137/BCBCR.S8323
PMID: 22259247
قاعدة البيانات: MEDLINE
الوصف
تدمد:1178-2234
DOI:10.4137/BCBCR.S8323